. Author manuscript; available in PMC: 2007 Jan 25.

Published in final edited form as: Future Oncol. 2006 Feb;2(1):137–143. doi: 10.2217/14796694.2.1.137

Table 2.

Outcome of clinical Phase 1/2 trials with replication-competent Ads.

Replication-competent Ads	Disease	Outcome	Refs
ONYX-015	Head and neck cancer (n = 24)	Rapid tumor progression in most patients	[63]
ONYX-015	Head and neck cancer (n = 37)	Combination of gene therapy and chemotherapy with cisplatin and 5-FU, reasonable response rates	[64]
ONYX-015	Pancreatic cancer (n = 23)	No responses after intratumoral virus application	[65]
ONYX-015	Metastatic liver cancer (n = 27)	Moderate responses with a combination of gene therapy and chemotherapy with 5-FU and leucovorin	[66]
ONYX-015	Metastatic colon cancer (n = 18)	Stable disease in 7 patients, moderate side effects	[67]
ONYX-015	Pancreatic cancer (n = 21)	Stable disease in 6 patients, combination of gene therapy and gemcitabine	[68]
CG7060	Prostate cancer (n = 20)	Intratumoral treatment, decrease of PSA levels	[69]
Ad5-CD/TKrep	Prostate cancer (n = 15)	Combination of radiotherapy and double-suicide gene therapy	[70]

Ad: Adenovirus; Ad5: Serotype 5; CD: Cytosine deaminase; CG7060: A PSA-specific, replication-competent adenovirus; FU: Fluorouracil; ONYX-015: An oncolytic adenovirus; PSA: Prostate-specific antigen; Ad5-CD/TKrep: Replication competent Ad.